Vita Therapeutics Closes $31 Million Series B Financing To Develop Cell Therapies For Neuromuscular Diseases And Cancers
Vita Therapeutics Closes $31 Million Series B Financing To Develop Cell Therapies For Neuromuscular Diseases And Cancers
10/12/22, 11:06 AM
Location
baltimoreMoney raised
$31 million
Round Type
series b
Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and cancers, today announced the completion of a $31 million Series B financing. The fundraise was led by Cambrian BioPharma and new investor Solve FSHD. New investors included Riptide Ventures and Cedars Sinai, which participated alongside TEDCO and other existing investors. Proceeds from the financing will be used to advance Vita’s lead pre-clinical program VTA-100 for limb-girdle muscular dystrophy (LGMD2A) to the clinic
Company Info
Location
1812 ashland avenue
baltimore, maryland, united states
Additional Info
We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform. Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.